Gina Capiaux is the Vice President of Regulatory Affairs at Sapience Therapeutics. Gina has over 25 years of experience in the biotechnology/pharmaceutical industry and 17 years in regulatory affairs. Prior to Sapience, Gina was Sr. Director at Ultragenyx Pharmaceutical, where she helped develop the regulatory affairs department and led multiple programs for rare genetic disorders including the enzyme replacement therapy MepseviiTM for mucopolysaccharidosis 7 (MPS 7) and DojolviTM for long-chain fatty acid oxidation disorders (LC-FAOD). Previously, she held positions of increasing responsibility at BioMarin Pharmaceutical, where she led the program for Vimizim® for (MPS 4) and various other small molecule and biologic programs. Her leadership has led to >30 successful IND/CTA applications, 6 NDA/BLA approvals, and numerous expedited program designations/approvals worldwide.
Dr. Capiaux holds a B.A. in biochemistry from California State University Fresno and a Ph.D. in Pharmacology from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan-Kettering Cancer Center.